Literature DB >> 22907230

Peripheral muscle weakness in RASopathies.

David A Stevenson1, Shawn Allen, William E Tidyman, John C Carey, David H Viskochil, Austin Stevens, Heather Hanson, Xiaoming Sheng, Brandi A Thompson, Megumi J Okumura, Kent Reinker, Barbara Johnson, Katherine A Rauen.   

Abstract

INTRODUCTION: RASopathies are a group of genetic conditions due to alterations of the Ras/MAPK pathway. Neurocutaneous findings are hallmark features of the RASopathies, but musculoskeletal abnormalities are also frequent. The objective was to evaluate handgrip strength in the RASopathies.
METHODS: Individuals with RASopathies (e.g., Noonan syndrome, Costello syndrome, cardio-facio-cutaneous [CFC] syndrome, and neurofibromatosis type 1 [NF1]) and healthy controls were evaluated. Two methods of handgrip strength were tested: GRIP-D Takei Hand Grip Dynamometer and the Martin vigorimeter. A general linear model was fitted to compare average strength among the groups, controlling for confounders such as age, gender, height, and weight.
RESULTS: Takei dynamometer: handgrip strength was decreased in each of the syndromes compared with controls. Decreased handgrip strength compared with sibling controls was also seen with the Martin vigorimeter (P < 0.0001).
CONCLUSIONS: Handgrip strength is decreased in the RASopathies. The etiology of the reduced muscle force is unknown, but likely multifactorial.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907230     DOI: 10.1002/mus.23324

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  15 in total

1.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

Review 2.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

3.  Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions.

Authors:  Bonnie Seaberg; Gabrielle Henslee; Shuo Wang; Ximena Paez-Colasante; Gary E Landreth; Mendell Rimer
Journal:  Mol Cell Biol       Date:  2015-01-20       Impact factor: 4.272

4.  NF1 is a critical regulator of muscle development and metabolism.

Authors:  Kate Sullivan; Jad El-Hoss; Kate G R Quinlan; Nikita Deo; Fleur Garton; Jane T C Seto; Marie Gdalevitch; Nigel Turner; Gregory J Cooney; Mateusz Kolanczyk; Kathryn N North; David G Little; Aaron Schindeler
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

5.  Update from the 2013 International Neurofibromatosis Conference.

Authors:  Scott R Plotkin; Anne C Albers; Dusica Babovic-Vuksanovic; Jaishri O Blakeley; Xandra O Breakefield; Courtney M Dunn; D Gareth Evans; Michael J Fisher; Jan M Friedman; Marco Giovannini; David H Gutmann; Michel Kalamarides; Andrea I McClatchey; Ludwine Messiaen; Helen Morrison; David B Parkinson; Anat O Stemmer-Rachamimov; Catherine D Van Raamsdonk; Vincent M Riccardi; Tena Rosser; Aaron Schindeler; Miriam J Smith; David A Stevenson; Nicole J Ullrich; Thijs van der Vaart; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette C Bakker; Alison C Lloyd
Journal:  Am J Med Genet A       Date:  2014-09-24       Impact factor: 2.802

6.  2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Michael J Fisher; Allan J Belzberg; Peter de Blank; Thomas De Raedt; Florent Elefteriou; Rosalie E Ferner; Marco Giovannini; Gordon J Harris; Michel Kalamarides; Matthias A Karajannis; AeRang Kim; Conxi Lázaro; Lu Q Le; Wei Li; Robert Listernick; Staci Martin; Helen Morrison; Eric Pasmant; Nancy Ratner; Elisabeth Schorry; Nicole J Ullrich; David Viskochil; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette Bakker; Eduard Serra
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.578

7.  Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.

Authors:  Srivandana Akshintala; Nashwa Khalil; Kaleb Yohay; Alona Muzikansky; Jeffrey Allen; Anna Yaffe; Andrea M Gross; Michael J Fisher; Jaishri O Blakeley; Beverly Oberlander; Miriam Pudel; Celia Engelson; Jaime Obletz; Carole Mitchell; Brigitte C Widemann; David A Stevenson; Scott R Plotkin
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

Review 8.  Fibroblast growth factor signaling in mammalian tooth development.

Authors:  Chun-Ying Li; Jan Prochazka; Alice F Goodwin; Ophir D Klein
Journal:  Odontology       Date:  2013-12-17       Impact factor: 2.885

9.  Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex.

Authors:  Lei Xing; Rylan S Larsen; George Reed Bjorklund; Xiaoyan Li; Yaohong Wu; Benjamin D Philpot; William D Snider; Jason M Newbern
Journal:  Elife       Date:  2016-02-05       Impact factor: 8.140

10.  Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.

Authors:  A Carlier; H Brems; J M A Ashbourn; I Nica; E Legius; L Geris
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.